A common language in neoadjuvant breast cancer clinical trials: Proposals for standard definitions and endpoints

Debora Fumagalli, Philippe L. Bedard, Zeina Nahleh, Stefan Michiels, Christos Sotiriou, Sherene Loi, Joseph A. Sparano, Matthew Ellis, Nola Hylton, Jo Anne Zujewski, Clifford Hudis, Laura Esserman, Martine Piccart

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

The neoadjuvant setting provides a unique opportunity to study the effect of systemic treatments on breast cancer biology and to identify clinically useful prognostic and predictive biomarkers. Discrepancies and inconsistencies in the use of definitions and endpoint assessments in this setting confound the analysis and interpretation of results across clinical trials and hinder research progress. This Review represents a joint effort of the Breast International Group and the National Cancer Institute-sponsored North American Breast Cancer Group to provide clinicians and researchers with a series of standardised definitions and endpoints that could be implemented in future neoadjuvant clinical trials. Definitions of the setting of interest and of survival endpoints are recommended, together with proposals for standard assessment of the response to treatment, use of functional and molecular imaging endpoints, and characterisation and selection of the population to treat. We expect that implementation of these recommendations will improve the conduct, reporting, and effectiveness of clinical trials and fully exploit the clinical and scientific potential of the neoadjuvant setting in breast cancer.

Original languageEnglish (US)
JournalThe Lancet Oncology
Volume13
Issue number6
DOIs
StatePublished - Jun 2012

Fingerprint

Language
Clinical Trials
Breast Neoplasms
Molecular Imaging
National Cancer Institute (U.S.)
Breast
Biomarkers
Research Personnel
Research
Population

ASJC Scopus subject areas

  • Oncology

Cite this

A common language in neoadjuvant breast cancer clinical trials : Proposals for standard definitions and endpoints. / Fumagalli, Debora; Bedard, Philippe L.; Nahleh, Zeina; Michiels, Stefan; Sotiriou, Christos; Loi, Sherene; Sparano, Joseph A.; Ellis, Matthew; Hylton, Nola; Zujewski, Jo Anne; Hudis, Clifford; Esserman, Laura; Piccart, Martine.

In: The Lancet Oncology, Vol. 13, No. 6, 06.2012.

Research output: Contribution to journalArticle

Fumagalli, D, Bedard, PL, Nahleh, Z, Michiels, S, Sotiriou, C, Loi, S, Sparano, JA, Ellis, M, Hylton, N, Zujewski, JA, Hudis, C, Esserman, L & Piccart, M 2012, 'A common language in neoadjuvant breast cancer clinical trials: Proposals for standard definitions and endpoints', The Lancet Oncology, vol. 13, no. 6. https://doi.org/10.1016/S1470-2045(11)70378-3
Fumagalli, Debora ; Bedard, Philippe L. ; Nahleh, Zeina ; Michiels, Stefan ; Sotiriou, Christos ; Loi, Sherene ; Sparano, Joseph A. ; Ellis, Matthew ; Hylton, Nola ; Zujewski, Jo Anne ; Hudis, Clifford ; Esserman, Laura ; Piccart, Martine. / A common language in neoadjuvant breast cancer clinical trials : Proposals for standard definitions and endpoints. In: The Lancet Oncology. 2012 ; Vol. 13, No. 6.
@article{fff5fd8bc45249b88470b618e9cdde83,
title = "A common language in neoadjuvant breast cancer clinical trials: Proposals for standard definitions and endpoints",
abstract = "The neoadjuvant setting provides a unique opportunity to study the effect of systemic treatments on breast cancer biology and to identify clinically useful prognostic and predictive biomarkers. Discrepancies and inconsistencies in the use of definitions and endpoint assessments in this setting confound the analysis and interpretation of results across clinical trials and hinder research progress. This Review represents a joint effort of the Breast International Group and the National Cancer Institute-sponsored North American Breast Cancer Group to provide clinicians and researchers with a series of standardised definitions and endpoints that could be implemented in future neoadjuvant clinical trials. Definitions of the setting of interest and of survival endpoints are recommended, together with proposals for standard assessment of the response to treatment, use of functional and molecular imaging endpoints, and characterisation and selection of the population to treat. We expect that implementation of these recommendations will improve the conduct, reporting, and effectiveness of clinical trials and fully exploit the clinical and scientific potential of the neoadjuvant setting in breast cancer.",
author = "Debora Fumagalli and Bedard, {Philippe L.} and Zeina Nahleh and Stefan Michiels and Christos Sotiriou and Sherene Loi and Sparano, {Joseph A.} and Matthew Ellis and Nola Hylton and Zujewski, {Jo Anne} and Clifford Hudis and Laura Esserman and Martine Piccart",
year = "2012",
month = "6",
doi = "10.1016/S1470-2045(11)70378-3",
language = "English (US)",
volume = "13",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "6",

}

TY - JOUR

T1 - A common language in neoadjuvant breast cancer clinical trials

T2 - Proposals for standard definitions and endpoints

AU - Fumagalli, Debora

AU - Bedard, Philippe L.

AU - Nahleh, Zeina

AU - Michiels, Stefan

AU - Sotiriou, Christos

AU - Loi, Sherene

AU - Sparano, Joseph A.

AU - Ellis, Matthew

AU - Hylton, Nola

AU - Zujewski, Jo Anne

AU - Hudis, Clifford

AU - Esserman, Laura

AU - Piccart, Martine

PY - 2012/6

Y1 - 2012/6

N2 - The neoadjuvant setting provides a unique opportunity to study the effect of systemic treatments on breast cancer biology and to identify clinically useful prognostic and predictive biomarkers. Discrepancies and inconsistencies in the use of definitions and endpoint assessments in this setting confound the analysis and interpretation of results across clinical trials and hinder research progress. This Review represents a joint effort of the Breast International Group and the National Cancer Institute-sponsored North American Breast Cancer Group to provide clinicians and researchers with a series of standardised definitions and endpoints that could be implemented in future neoadjuvant clinical trials. Definitions of the setting of interest and of survival endpoints are recommended, together with proposals for standard assessment of the response to treatment, use of functional and molecular imaging endpoints, and characterisation and selection of the population to treat. We expect that implementation of these recommendations will improve the conduct, reporting, and effectiveness of clinical trials and fully exploit the clinical and scientific potential of the neoadjuvant setting in breast cancer.

AB - The neoadjuvant setting provides a unique opportunity to study the effect of systemic treatments on breast cancer biology and to identify clinically useful prognostic and predictive biomarkers. Discrepancies and inconsistencies in the use of definitions and endpoint assessments in this setting confound the analysis and interpretation of results across clinical trials and hinder research progress. This Review represents a joint effort of the Breast International Group and the National Cancer Institute-sponsored North American Breast Cancer Group to provide clinicians and researchers with a series of standardised definitions and endpoints that could be implemented in future neoadjuvant clinical trials. Definitions of the setting of interest and of survival endpoints are recommended, together with proposals for standard assessment of the response to treatment, use of functional and molecular imaging endpoints, and characterisation and selection of the population to treat. We expect that implementation of these recommendations will improve the conduct, reporting, and effectiveness of clinical trials and fully exploit the clinical and scientific potential of the neoadjuvant setting in breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84861553242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861553242&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(11)70378-3

DO - 10.1016/S1470-2045(11)70378-3

M3 - Article

C2 - 22652232

AN - SCOPUS:84861553242

VL - 13

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 6

ER -